Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease

• Published in: Clinical interventions in aging Vol. 12; pp. 1271 - 1279
• Main Authors: Zhang, J W, Liu, W W, McCaffrey, Timothy A, He, X Q, Liang, W Y, Chen, X H, Feng, X R, Fu, Sidney W, Liu, M L
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2017; Taylor & Francis Ltd; Dove Medical Press
• Subjects: Adenosine diphosphate; Age; Aged; Aged, 80 and over; Angina pectoris; Apoptosis; Aspirin; Aspirin - adverse effects; Blood platelets; Cardiovascular disease; Cardiovascular Diseases - drug therapy; Cholesterol; Complications and side effects; Coronary Artery Disease - drug therapy; Coronary heart disease; Coronary vessels; Dosage and administration; Drug therapy; elderly; Elderly patients; Female; Geriatrics; Health aspects; Hemoglobin; high on-aspirin platelet reactivity; Hospitals; Humans; Intervention; Male; Medical imaging; Middle Aged; Older people; Original Research; Physiological aspects; Platelet activation; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - adverse effects; Platelet Count; Platelet Function Tests; Purinergic P2Y Receptor Antagonists - administration & dosage; Risk Factors; Thrombosis; Thrombosis - chemically induced; Uric acid; Uric Acid - blood; Beijing China; China; coronary artery disease; aspirin; platelet reactivity; risk factors; elderly
• ISSN: 1178-1998; 1176-9092; 1178-1998
• DOI: 10.2147/CIA.S138592

Previous studies have illustrated the link between high on-aspirin platelet reactivity (HAPR) with increasing thrombotic risks. The aim of our study was to investigate relative risk factors of HAPR in elderly patients with coronary artery disease. Elderly, hospitalized coronary artery disease patients on regular aspirin treatment were enrolled from January 2014 to September 2016. Medical records of each patient were collected, including demographic information, cardiovascular risk factors, concomitant drugs and routine biological parameters. Arachidonic acid (AA, 0.5 mg/mL) and adenosine diphosphate (ADP, 5 µmol/L) induced platelet aggregation were measured via light transmission assay (LTA) to evaluate antiplatelet responses, referred as LTA-AA and LTA-ADP. A total of 275 elderly patients were included, with mean age of 77.2±8.1 years, and males accounted for 81.8%. HAPR was defined as LTA-AA in the upper quartile of the enrolled population. HAPR patients tended to have lower renal function ( =0.052). Higher serum uric acid (SUA) level, as well as lower platelet count, hemoglobin and hematocrit were observed in HAPR patients, with a higher proportion of diuretics use ( <0.05). Multivariate analysis revealed that SUA (OR: 1.004, 95% CI: 1.000-1.007, =0.048), platelet count (OR: 0.994, 95% CI: 0.989-1.000, =0.045), hematocrit (OR: 0.921, 95% CI: 0.864-0.981, =0.011) and concomitant P2Y12 receptor inhibitors use (OR: 1.965, 95% CI: 1.075-3.592, =0.028) were correlated with HAPR. Spearman's correlation analysis demonstrated an inverse association of LTA-AA with hematocrit ( =-0.234, <0.001), hemoglobin ( =-0.209, <0.001) and estimated glomerular filtration rate ( =-0.132, =0.031). SUA, platelet count, hematocrit and P2Y12 receptor inhibitors use were independently correlated with HAPR. These parameters might provide novel therapeutic targets for optimizing antiplatelet therapy.